CLAIM #12143 · Bristol-Myers Squibb Company (BMY) · 2025Q1 earnings call · Apr 24, 2025 · due Mar 31, 2026
“For MEVI, there's a lot of excitement there around the potency of the sacitamab, which has the opportunity to read out as well potentially in early 2026.”
Samit Hirawat · Chief Medical Officer
PENDING
graded after results covering Mar 31, 2026 are reported
Verify independently
SEC filings for BMY ↗ · Claim quote is verbatim from the 2025Q1 earnings call.